TRPM8 and steatosis: Furthermore, concentration‐dependent inhibition of steatosis and fibrosis was replicated for selumetinib (MAP2K1 inhibitor), MK‐2206 (AKT inhibitor), and PF‐05105679 (TRPM8 inhibitor).